Albert David Ltd.

Financial

	Albert David	Brooks Laboratories	Lyka Labs
Operational Metrics
Pharmaceutical Sector
R&D as a % of Total Sales	0.54 %	n/a	n/a
Financials
5 yr Average ROE	12.32 %	-23.88 %	145.3 %
5yr average Equity Multiplier	1.67	1.78	-0.06
5yr Average Asset Turnover Ratio	0.67	0.6	0.64
5yr Avg Net Profit Margin	11.52 %	-23.79 %	-21.64 %
Price to Book	1.28	4.38	3.93
P/E	29.3	0.0	50.8
5yr Avg Cash Conversion Cycle	-59.38 Days	-10.34 Days	16.94 Days
Inventory Days	46.72 Days	93.5 Days	26.54 Days
Days Receivable	28.39 Days	66.75 Days	77.33 Days
Days Payable	118.01 Days	179.8 Days	133.6 Days
5yr Average Interest Coverage Ratio	90.39	-11.84	0.6
5yr Avg ROCE	15.83 %	-15.03 %	22.35 %
5yr Avg Operating Profit Margin	11.27 %	-13.23 %	20.24 %
5 yr average Debt to Equity	0.01	0.21	-0.79
5yr CAGR Net Profit	31.51 %	0.22 %	-47.18 %
5yr Average Return on Assets	7.45 %	-14.62 %	-5.63 %
Shareholdings
Promoter Holding	62.24 %	52.62 %	58.16 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.28 %	-13.79 %	10.37 %
Change in Mutual Fund Holding (3 Yrs)	0.0	9.9 %	-0.72 %

Business

	Albert David	Brooks Laboratories	Lyka Labs
Product Wise Break-Up	Product Wise Break-Up Pharmaceutical 100.0 Formulations 0 Bulk Drugs 0	Product Wise Break-Up Bulk Drugs 0 Pharmaceutical 0 Formulations 0 Others 100	Product Wise Break-Up Bulk Drugs 3.2 Pharmaceutical 0 Formulations 96.8
Location Wise Break-Up	Location Wise Break-Up India 92.79 Rest of the World 7.21 International 0 Domestic 0	-	Location Wise Break-Up International 39.91 Rest of the World 0 India 0 India 60.09
Dosage Form Break-Up	Dosage Form Break-Up LVP – Large volume Parenteral 27.77 Syrup 19.48 SVP – Small volume Parenteral 18.51 Tablet 15.8 Capsule 9.04 Ointment 8.18 Others 1.22	-	-
Customer Wise Break-Up	Customer Wise Break-Up Non Government 95.2 Government 4.8	-	-